pSivida (PSDV) Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien Study
Tweet Send to a Friend
pSivida Corp (NASDAQ: PSDV) reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
